247 related articles for article (PubMed ID: 24505322)
1. Effects of the ß2-adrenoceptor agonist, albuterol, in a mouse model of anti-MuSK myasthenia gravis.
Ghazanfari N; Morsch M; Tse N; Reddel SW; Phillips WD
PLoS One; 2014; 9(2):e87840. PubMed ID: 24505322
[TBL] [Abstract][Full Text] [Related]
2. Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction.
Cole RN; Reddel SW; Gervásio OL; Phillips WD
Ann Neurol; 2008 Jun; 63(6):782-9. PubMed ID: 18384168
[TBL] [Abstract][Full Text] [Related]
3. Efgartigimod improves muscle weakness in a mouse model for muscle-specific kinase myasthenia gravis.
Huijbers MG; Plomp JJ; van Es IE; Fillié-Grijpma YE; Kamar-Al Majidi S; Ulrichts P; de Haard H; Hofman E; van der Maarel SM; Verschuuren JJ
Exp Neurol; 2019 Jul; 317():133-143. PubMed ID: 30851266
[TBL] [Abstract][Full Text] [Related]
4. Pyridostigmine but not 3,4-diaminopyridine exacerbates ACh receptor loss and myasthenia induced in mice by muscle-specific kinase autoantibody.
Morsch M; Reddel SW; Ghazanfari N; Toyka KV; Phillips WD
J Physiol; 2013 May; 591(10):2747-62. PubMed ID: 23440963
[TBL] [Abstract][Full Text] [Related]
5. The mouse passive-transfer model of MuSK myasthenia gravis: disrupted MuSK signaling causes synapse failure.
Ghazanfari N; Trajanovska S; Morsch M; Liang SX; Reddel SW; Phillips WD
Ann N Y Acad Sci; 2018 Jan; 1412(1):54-61. PubMed ID: 29125188
[TBL] [Abstract][Full Text] [Related]
6. Muscle specific kinase autoantibodies cause synaptic failure through progressive wastage of postsynaptic acetylcholine receptors.
Morsch M; Reddel SW; Ghazanfari N; Toyka KV; Phillips WD
Exp Neurol; 2012 Oct; 237(2):286-95. PubMed ID: 22789393
[TBL] [Abstract][Full Text] [Related]
7. 3,4-Diaminopyridine improves neuromuscular transmission in a MuSK antibody-induced mouse model of myasthenia gravis.
Mori S; Kishi M; Kubo S; Akiyoshi T; Yamada S; Miyazaki T; Konishi T; Maruyama N; Shigemoto K
J Neuroimmunol; 2012 Apr; 245(1-2):75-8. PubMed ID: 22409941
[TBL] [Abstract][Full Text] [Related]
8. Passive and active immunization models of MuSK-Ab positive myasthenia: electrophysiological evidence for pre and postsynaptic defects.
Viegas S; Jacobson L; Waters P; Cossins J; Jacob S; Leite MI; Webster R; Vincent A
Exp Neurol; 2012 Apr; 234(2):506-12. PubMed ID: 22326541
[TBL] [Abstract][Full Text] [Related]
9. Antibodies against muscle-specific kinase impair both presynaptic and postsynaptic functions in a murine model of myasthenia gravis.
Mori S; Kubo S; Akiyoshi T; Yamada S; Miyazaki T; Hotta H; Desaki J; Kishi M; Konishi T; Nishino Y; Miyazawa A; Maruyama N; Shigemoto K
Am J Pathol; 2012 Feb; 180(2):798-810. PubMed ID: 22142810
[TBL] [Abstract][Full Text] [Related]
10. MuSK induced experimental autoimmune myasthenia gravis does not require IgG1 antibody to MuSK.
Küçükerden M; Huda R; Tüzün E; Yılmaz A; Skriapa L; Trakas N; Strait RT; Finkelman FD; Kabadayı S; Zisimopoulou P; Tzartos S; Christadoss P
J Neuroimmunol; 2016 Jun; 295-296():84-92. PubMed ID: 27235354
[TBL] [Abstract][Full Text] [Related]
11. Guidelines for pre-clinical animal and cellular models of MuSK-myasthenia gravis.
Phillips WD; Christadoss P; Losen M; Punga AR; Shigemoto K; Verschuuren J; Vincent A
Exp Neurol; 2015 Aug; 270():29-40. PubMed ID: 25542979
[TBL] [Abstract][Full Text] [Related]
12. Pre- and postsynaptic neuromuscular junction abnormalities in musk myasthenia.
Niks EH; Kuks JB; Wokke JH; Veldman H; Bakker E; Verschuuren JJ; Plomp JJ
Muscle Nerve; 2010 Aug; 42(2):283-8. PubMed ID: 20544919
[TBL] [Abstract][Full Text] [Related]
13. Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis.
Pevzner A; Schoser B; Peters K; Cosma NC; Karakatsani A; Schalke B; Melms A; Kröger S
J Neurol; 2012 Mar; 259(3):427-35. PubMed ID: 21814823
[TBL] [Abstract][Full Text] [Related]
14. Forced expression of muscle specific kinase slows postsynaptic acetylcholine receptor loss in a mouse model of MuSK myasthenia gravis.
Ghazanfari N; Linsao EL; Trajanovska S; Morsch M; Gregorevic P; Liang SX; Reddel SW; Phillips WD
Physiol Rep; 2015 Dec; 3(12):. PubMed ID: 26702075
[TBL] [Abstract][Full Text] [Related]
15. β2-Adrenergic receptor agonists ameliorate the adverse effect of long-term pyridostigmine on neuromuscular junction structure.
Vanhaesebrouck AE; Webster R; Maxwell S; Rodriguez Cruz PM; Cossins J; Wickens J; Liu WW; Cetin H; Cheung J; Ramjattan H; Palace J; Beeson D
Brain; 2019 Dec; 142(12):3713-3727. PubMed ID: 31633155
[TBL] [Abstract][Full Text] [Related]
16. Specific binding of collagen Q to the neuromuscular junction is exploited to cure congenital myasthenia and to explore bases of myasthenia gravis.
Ohno K; Ito M; Kawakami Y; Krejci E; Engel AG
Chem Biol Interact; 2013 Mar; 203(1):335-40. PubMed ID: 22981737
[TBL] [Abstract][Full Text] [Related]
17. Acute severe animal model of anti-muscle-specific kinase myasthenia: combined postsynaptic and presynaptic changes.
Richman DP; Nishi K; Morell SW; Chang JM; Ferns MJ; Wollmann RL; Maselli RA; Schnier J; Agius MA
Arch Neurol; 2012 Apr; 69(4):453-60. PubMed ID: 22158720
[TBL] [Abstract][Full Text] [Related]
18. Altered active zones, vesicle pools, nerve terminal conductivity, and morphology during experimental MuSK myasthenia gravis.
Patel V; Oh A; Voit A; Sultatos LG; Babu GJ; Wilson BA; Ho M; McArdle JJ
PLoS One; 2014; 9(12):e110571. PubMed ID: 25438154
[TBL] [Abstract][Full Text] [Related]
19. Muscle-specific kinase (MuSK) autoantibodies suppress the MuSK pathway and ACh receptor retention at the mouse neuromuscular junction.
Ghazanfari N; Morsch M; Reddel SW; Liang SX; Phillips WD
J Physiol; 2014 Jul; 592(13):2881-97. PubMed ID: 24860174
[TBL] [Abstract][Full Text] [Related]
20. Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice.
Klooster R; Plomp JJ; Huijbers MG; Niks EH; Straasheijm KR; Detmers FJ; Hermans PW; Sleijpen K; Verrips A; Losen M; Martinez-Martinez P; De Baets MH; van der Maarel SM; Verschuuren JJ
Brain; 2012 Apr; 135(Pt 4):1081-101. PubMed ID: 22396395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
